Harbour BioMed, the global biopharmaceutical company specialising in novel antibody therapeutics in immunology and oncology, has announced the appointment of Yajie Li as its new Chief Medical Officer (CMO).
Based in Shanghai, Ms. Li will report directly to Harbour BioMed’s Founder, Chairman and Chief Executive Officer, Dr. Jingsong Wang. In her new role, she will oversee clinical development, regulatory strategy and medical affairs across the company’s clinical-stage programmes. She will also contribute to the assessment of early-stage assets, focusing on unmet medical needs, scientific differentiation and clinical value.
Ms. Li brings over ten years of experience in the pharmaceutical sector, having held leadership posts in clinical development and regulatory affairs at major global corporations and contract research organisations including Merck, Johnson & Johnson and Parexel. Her career also includes senior positions at Chinese biopharmaceutical firms such as GenSci, XuanZhu Biopharm and Innovent.
Earlier in her career, she worked for nearly a decade at the National Medical Products Administration of China (NMPA) within the Centre for Drug Evaluation (CDE), where she served as a Senior Medical Officer. During her time there, she played a significant role in regulatory reviews spanning multiple therapeutic areas.
Welcoming the appointment, Dr. Wang said: “We are very pleased to welcome Yajie Li to our executive team. Her deep expertise in clinical development and regulatory science will further strengthen our capabilities as we advance our pipeline and grow into a therapeutically focused biopharma company. We look forward to her leadership in delivering transformative medicines to patients around the world.”
Commenting on her new position, Ms. Li said: “It is a great honor to join Harbour BioMed as Chief Medical Officer at this pivotal stage of its growth. The company’s cutting-edge antibody technology platform and global R&D strategy is well positioned to deliver innovative therapies in areas of high unmet need. I look forward to working with the team to accelerate clinical development, enhance regulatory alignment, and bring meaningful treatments to patients worldwide.”
Ms. Li holds a master’s degree in Rheumatology and Immunology from Peking Union Medical College.
